Shows
OncotargetEfficacy of Pembrolizumab with sEphB4-HSA in HPV-negative EphrinB2-positive HNSCCBUFFALO, NY- July 22, 2024 – A new #research paper was #published in Oncotarget's Volume 15 on July 10, 2024, entitled, “Improved efficacy of pembrolizumab combined with soluble EphB4-albumin in HPV-negative EphrinB2 positive head neck squamous cell carcinoma.”
Patients with relapsed or metastatic head and neck squamous cell carcinoma (HNSCC) after primary local therapy have low response rates with cetuximab, systemic chemotherapy or check point inhibitor therapy. Novel combination therapies with the potential to improve outcomes for patients with HNSCC is an area of high unmet need.
In this new study, researchers Alexandra Jackovich, Barbara J. Gitlitz, Justin Wayne Wong Tiu-lim, Vinay Duddalwar, Kevin George King...2024-07-2203 min
Periodismo AdaptadoMinimizados / Episodio 2: Un grupo de mujeres llevan adelante el comedor y merendero "Esos Locos Bajitos"¡"Sabemos que no podemos cambiar el mundo, pero con nuestro granito de arena podemos modificar muchas cosas"!
En el segundo capítulo de "Minimizados", Franco Nieva, dialogó con Barbara Rocco, quien actualmente es responsable y fundadora del comedor y merendero "Esos locos bajitos" situado en Sarandí, Provincia de Buenos Aires, Argentina.
Allí un grupo de once madres vecinas del barrio colaboran día a día asistiendo social, nutricional y humanamente a los 170 niños y 70 familias que se acercan todas las semanas para alimentarse.
"Somos un grupo de mujeres que comp...2022-02-1021 min
OncotargetLung Cancer Antigen Expression Characterized by Molecular SubtypeLung cancer continues to be the leading cause of cancer deaths world-wide. Variations in the stage of diagnosis, subtypes and types of mutated genes provide a challenge for researchers who are developing targeted treatments to help rid patients of lung cancer. To this end, many researchers are interested in employing cancer-testis antigens (CTAs), which are minimally expressed in normal tissues, but strongly expressed in solid tumors. Therefore, CTAs are appealing therapeutic targets. The Kita-Kyushu lung cancer antigen-1 (also known as KK-LC-1; CT 83; CXORF61) is a CTA that is expressed in 82% of gastric tumors, 53% of breast cancers (higher in triple-negative breast...2021-12-0907 min